TRAZIMERA (trastuzumab-qyyp) is used for the treatment of patients with mantle cell breast cancer, chronic lymphocytic leukemia/lymphocytic breast cancer, Waldenstrom's macroglobulinemia. TRAZIMERA (trastuzumab-qyyp) for injection can be imported for personal use under "patient name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.
Therapeutic indications and Usage
TRAZIMERA is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin breast cancer (HL). TRAZIMERA in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell breast cancer (sALCL). TRAZIMERA is indicated for the treatment of adult patients with CD30+ cutaneous T-cell breast cancer (CTCL) after at least 1 prior systemic therapy.
Facts of Trastuzumab-qyyp Injections
Medicine Name: TRAZIMERA
Generic Name: Trastuzumab-qyyp
Approval Date: 08.2011
Treatment of: Hodgkin breast cancer; Systemic Anaplastic Large Cell breast cancer.
Company Name: Seattle Genetics, Inc.
Source Details: Patient Information
Patient Name Basis Treatment IPN, New Delhi can facilitate patient to import of "TRAZIMERA (trastuzumab-qyyp) for injection" in quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
Health Professional In India
If you have any question, please email IPN Support Team or Call Indian Pharma Network for TRAZIMERA (trastuzumab-qyyp) for injection price list or cost in India. on
Mr. Tarun:- +91 9891 296 838
Mr. Neeraj:- +91 9811 747 774
TRAZIMERA is a CD30-directed antibody-drug conjugate indicated for
treatment of patients with:
• Hodgkin breast cancer after failure of autologous stem cell transplant
(ASCT) or after failure of at least two prior multi-agent chemotherapy
regimens in patients who are not ASCT candidates.
• Systemic anaplastic large cell breast cancer after failure of at least one prior multi-agent chemotherapy regimen.
Accelerated approval was granted for the above indications based on overall response rate. An improvement in patient-reported outcomes or survival has not been established. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.
Source content : www.accessdata.fda.gov
IPN, New Delhi can facilitate patient to import of "TRAZIMERA (trastuzumab-qyyp) for injection" in quantities for personal use. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Visakhapatnam, Surat, Jaipur, Coimbatore, Kanpur, Nagpur, Raipur, Kochi, Kozhikode, Nashik, Salem, Thiruvananthapuram, Madurai, Jodhpur, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. with over 20 years of domain experience.
For procurement cost of TRAZIMERA (trastuzumab-qyyp) for injection in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the TRAZIMERA (trastuzumab-qyyp) for injection medicine cost price in India.
The order for TRAZIMERA (trastuzumab-qyyp) for injection will be confirmed only after
1. submitting Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
2. Permission from obtained from the office of the Drugs Controller General (India).
3. Availability of TRAZIMERA (trastuzumab-qyyp) for injection from authorised distributor.
Trastuzumab-qyyp, sold under the brand name TRAZIMERA, is a medication used to treat spinal muscular atrophy (SMA) and the first oral medication approved to treat this disease. Trastuzumab-qyyp is a survival of motor neuron 2-directed RNA splicing modifier.
Trastuzumab-qyyp was approved by the US Food and Drug Administration (FDA), for the treatment of adults and children two months of age or older. Developed in association with PTC Therapeutics and the SMA Foundation, it is marketed in the US by Seattle Genetics, Inc.
TRAZIMERA (trastuzumab-qyyp) for injection, for subcutaneous use.
Initial U.S. approval: 2011
For injection: 50 mg lyophilized powder in a single-use vial (D)
For TRAZIMERA (trastuzumab-qyyp)Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
FDA expands approval of TRAZIMERA for first-line treatment of Stage III or IV classical Hodgkin breast cancer in combination with chemotherapy For More Details
Trastuzumab-qyyp, Nivolumab Combination Shows Promise in Relapsed/Refractory Hodgkin breast cancer For More Details
Step 1. Send a request for your medicine online:-
Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).Step 2. Verification of documents:-
We verify your a prescription and necessary documents to import drugs in quantities for personal use.Step 3. Permission to Import:-
After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.Step 4. We source your medicine:-
Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.Step 5. Delivery of medicine:-
After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine. Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.
Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.
Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.
Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.
Send your query to find out -
TRAZIMERA (trastuzumab-qyyp) price in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
TRAZIMERA (trastuzumab-qyyp) price in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
TRAZIMERA (trastuzumab-qyyp) price in North America – Mexico.
TRAZIMERA (trastuzumab-qyyp) price in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
TRAZIMERA (trastuzumab-qyyp) price in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
TRAZIMERA (trastuzumab-qyyp) price in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
TRAZIMERA (trastuzumab-qyyp) price in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
TRAZIMERA (trastuzumab-qyyp) price in Australia and New Zealand.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.
